Methergin

Methylergometrine Maleate, the active ingredient in Methergin, is an ergot alkaloid presented as an injectable solution for intramuscular, intravenous, and subcutaneous use. It treats postpartum hemorrhage, manages uterine atony, and can be employed to facilitate labor induction in women.

GNH USA supplies Methergin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics, and procurement teams worldwide, providing reliable access to this essential obstetric medication. The company adheres to stringent quality standards and offers global logistics support.

Methergin, containing methylergometrine maleate, is used in obstetric care to promote uterine contraction and control bleeding.

- Postpartum hemorrhage: controls severe bleeding by inducing strong uterine contractions. - Uterine atony: restores uterine tone to prevent excessive blood loss after delivery. - Labor induction (selected protocols): stimulates cervical ripening and uterine activity to initiate labor.

Methylergometrine maleate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Headache - Transient hypertension

Serious or Rare Side Effects: - Severe hypertension or hypertensive crisis - Myocardial ischemia or infarction - Pulmonary edema - Allergic reactions including anaphylaxis

When using Methergin, clinicians should observe several safety precautions to minimize risks.

- Assess cardiovascular status: monitor blood pressure before and during administration. - Avoid use in uncontrolled hypertension: risk of severe blood pressure elevation. - Use cautiously in patients with coronary artery disease: possible myocardial ischemia. - Do not combine with other ergot alkaloids: additive vasoconstriction may occur. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methylergometrine maleate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Concomitant use with vasoconstrictors (e.g., ergotamine): risk of severe vasospasm. - Combination with monoamine oxidase inhibitors: may precipitate hypertensive crisis. - Co‑administration with other uterotonics in high doses (e.g., oxytocin): can cause excessive uterine contraction.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt cardiovascular response to methylergometrine. - Calcium channel blockers: may alter uterine contractility and affect efficacy. - Antihypertensive agents: may require dose adjustment and close blood pressure monitoring.